Royalty Pharma plc financial data

Symbol
RPRX on Nasdaq
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 05 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 168 % -59.7%
Return On Equity 7.79 % -32%
Return On Assets 4.16 % -38%
Operating Margin 65.2 % -4.27%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 13.1B USD -4.38%
Weighted Average Number of Shares Outstanding, Basic 432M shares -3.52%
Weighted Average Number of Shares Outstanding, Diluted 560M shares -5.59%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.35B USD +3.7%
Research and Development Expense 402M USD +20000%
General and Administrative Expense 477M USD +109%
Costs and Expenses 817M USD +13.2%
Operating Income (Loss) 1.53B USD -0.72%
Nonoperating Income (Expense) -230M USD -235%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 1.3B USD -24%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent 765M USD -33.2%
Earnings Per Share, Basic 1 USD/shares -31.9%
Earnings Per Share, Diluted 1 USD/shares -31.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 939M USD -1.17%
Other Assets, Current 5.52M USD +11.1%
Assets, Current 1.85B USD +3.09%
Goodwill 925M USD
Other Assets, Noncurrent 86.6M USD +102%
Assets 19.3B USD +7.23%
Liabilities, Current 531M USD -54.5%
Other Liabilities, Noncurrent 127M USD +2175%
Liabilities 9.73B USD +25%
Retained Earnings (Accumulated Deficit) 2.3B USD -16.7%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 9.62B USD -6.22%
Liabilities and Equity 19.3B USD +7.23%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 596M USD -10.3%
Net Cash Provided by (Used in) Financing Activities -941M USD -344%
Net Cash Provided by (Used in) Investing Activities 504M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 159M USD -56.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 939M USD -1.17%
Interest Paid, Excluding Capitalized Interest, Operating Activities 139M USD +75.8%
Operating Lease, Liability 20M USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 1.13B USD +4401%
Lessee, Operating Lease, Liability, to be Paid 23.2M USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.78M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 4.05M USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.15M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.72M USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.73M USD
Additional Paid in Capital 4.11B USD +0.12%
Amortization of Intangible Assets 0 USD -100%
Share-based Payment Arrangement, Expense 73.4M USD +10188%
Interest Expense 184M USD -1.8%